Related Experiment Video
Updated: Feb 11, 2026
06:52
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
1.8K
Pharmacotherapy for retinoblastoma.
Mohsen Shahsavari1, Arman Mashayekhi
1Labbafinejad Medical Center, Shahid Beheshti University, MC, Tehran, Iran.
Journal of Ophthalmic & Vision Research
|December 1, 2012
Summary
Systemic chemotherapy is the primary treatment for retinoblastoma, a dangerous infantile eye cancer. New drugs and delivery methods may soon transform treatment outcomes for this condition.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Medical Pharmacology
Background:
- Retinoblastoma is a common, sight-threatening infantile ocular neoplasm.
- Systemic chemotherapy is the current standard of care for retinoblastoma.
- Current treatments face challenges in efficacy and toxicity.
Purpose of the Study:
- To review advancements in chemotherapy for retinoblastoma.
- To explore novel chemotherapeutic and antiangiogenesis agents.
- To discuss innovative drug administration routes for retinoblastoma.
Main Methods:
- Literature review of recent studies on retinoblastoma treatment.
- Analysis of novel chemotherapeutic agents and antiangiogenesis drugs.
- Evaluation of periocular, intravitreal, and intra-ophthalmic artery injection techniques.
Main Results:
- Systemic chemotherapy remains the cornerstone of retinoblastoma management.
- Emerging chemotherapeutic and antiangiogenesis agents show promise.
- New drug delivery routes offer targeted treatment options.
Conclusions:
- Novel agents and administration routes have the potential to revolutionize retinoblastoma treatment.
- These advancements may improve outcomes for this infantile ocular neoplasm.
- Further research is needed to fully integrate these innovations into clinical practice.
Related Concept Videos
01:20The Retinoblastoma Gene
4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
01:26Psychosis: Goals of Pharmacotherapy
543
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
543
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:23Negative Regulator Molecules
38.6K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.6K